Anavex Life Sciences Corp (AVXL)
EBITDA Growth
77.79%
Quarterly · Period ending:
AVXL EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported77.79%period ending
Latest reported77.79%period ending
AVXL Quarterly EBITDA YoY % (-129.55% → 77.79%)
Year-over-year change
High-resolution chart · PNG
AVXL ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| 77.7941% | |
| 47.7813% | |
| 58.299% | |
| 44.7803% | |
| -1.6339% | |
| -2.1807% | |
| -57.5041% | |
| -15.0208% | |
| -25.2514% | |
| -0.4879% | |
| 33.6361% | |
| 27.484% | |
| 8.4691% | |
| -16.1893% | |
| -19.7156% | |
| -21.6328% | |
| -21.0803% | |
| -16.3717% | |
| -54.1839% | |
| -25.0992% | |
| -16.1793% | |
| 100% | |
| -19.7183% | |
| -14.6241% | |
| 4.5535% | |
| -3.0649% | |
| -7.8565% | |
| -55.6565% | |
| -70.3571% | |
| -80.8109% | |
| -12.3001% | |
| -24.9529% | |
| -31.7964% | |
| -30.5971% | |
| 21.0101% | |
| -61.9201% | |
| -66.846% | |
| 20.1081% | |
| -22.3417% | |
| -48.4519% | |
| -150.9109% | |
| -452.82% | |
| 44.8206% | |
| -51.2098% | |
| 15.3414% | |
| -295.9206% | |
| -225.9602% | |
| -629.8558% | |
| -1,033.3755% | |
| 181.7737% | |
| -193.8516% | |
| 96.9465% | |
| 89.0277% | |
| 78.8485% | |
| 358.8459% | |
| -185.5905% | |
| 58.5483% | |
| -53.1963% | |
| 37.4778% | |
| -20.6584% | |
| -17.0743% | |
| -208.5569% | |
| -8.8957% | |
| -3.6463% | |
| -118.1424% | |
| 51.1012% | |
| 33.0635% | |
| -26.9345% | |
| -14.6172% | |
| 8.2761% | |
| -135.8586% | |
| -287.4308% | |
| -297.985% | |
| -7,902.9338% | |
| -19,417.0744% | |
| -4,399.4542% | |
| -3,521.9528% | |
| -31.1683% | |
| 85.9983% | |
| 87.5706% | |
| 89.8026% | |
| -129.551% |